Treatment of Small Vessel Disease With the Paclitaxel Drug‐Eluting Balloon: 6‐Month Angiographic and 1‐Year Clinical Outcomes of the Spanish Multicenter Registry

Publisher： John Wiley & Sons Inc

E-ISSN： 1540-8183|28|5|430-438

ISSN： 0896-4327

Source： JOURNAL OF INTERVENTIONAL CARDIOLOGY, Vol.28, Iss.5, 2015-10, pp. : 430-438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug-Eluting Balloon Technology for Native Non-Small Coronary Artery Disease: Another Crusade against Skepticism!

By  

Cardiology, Vol. 137, Iss. 1, 2016-12 ,pp. : 22-24

Karger

Access to resources Recommend Favorite

Stellarex drug‐coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12‐Month results from a prospective, multicenter, single‐arm study

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 497-504

John Wiley & Sons Inc

Access to resources Recommend Favorite

Temporal patterns of drug‐eluting stent failure and its relationship with clinical outcomes

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. 4, 2015-03 ,pp. : 515-521

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of 2‐year clinical outcomes between zotarolimus‐, sirolimus‐, and paclitaxel‐eluting stents in real life clinical practice

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 349-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

First‐in‐man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus‐eluting stent in the treatment of patients with de novo coronary lesions: Clinical, Angiographic, and OCT outcomes of CREDIT‐1

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. S1, 2015-03 ,pp. : 744-751

John Wiley & Sons Inc

Access to resources Recommend Favorite